news
Memory T cells respond to SARS-CoV-2 Omicron variant, study shows
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
List view / Grid view
T cells
news
Novel nanotherapy offers hope for potential treatment of type 1 diabetes
Researchers have developed rapamycin-loaded nanocarriers capable of targeting cells related to pancreatic islet transplants without suppressing wider immune responses.
article
CRISPR screens and novel drug targets
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
article
T-cell immunotherapies and flow cytometry
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
news
Nanotechnology boosts immune response at tumour site in mice
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
news
Scientists discover mechanism that links autism and intestinal inflammation
The new research shows how interleukin-17a (IL-17a) can alter the trajectory of immune system development and cause gut inflammation.
article
“Off-the-shelf” immunotherapies for cancer
In this article, Drug Target Review's Victoria Rees explores a new method that could enable powerful immune cells to be produced in large quantities to treat a range of cancers.
news
Rheumatoid arthritis discovery may lead to novel inflammation blockers
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
news
Replication proteins a potential new target for COVID-19 vaccines
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
podcasts
Episode 3 – Cell & gene therapy with Dr Sam Wadsworth, Ultragenyx Pharmaceutical & Dr Eric Ostertag, Poseida Therapeutics
Tune in to this podcast to learn about AAV vectors for gene therapy delivery and engineering CAR T cells against solid tumours.
video
Engineering better CAR T cells with Professor Ann Ager, Cardiff University
Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
news
Novel strategy successfully suppresses HIV infection in mice
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
article
High-throughput 3D cell migration assays in organ-on-a-chip technologies
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
news
Antidepressants inhibit growth of pancreatic and colon cancers in mice
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
news
New AI method could aid in development of T cell-based cancer therapies
An artificial intelligence technique can identify which neoantigens are recognised by the immune system, possibly improving cancer prognosis and treatment.